Tepadina® (thiotepa) – New Drug Approval
January 26, 2017 – The FDA approved Adienne’s Tepadina (thiotepa) to reduce the risk of graft rejection when used in conjunction with high-dose busulfan (Busulfex®) and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia; for the treatment of adenocarcinoma of the breast or ovary; for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities; and for the treatment of superficial papillary carcinoma of the urinary bladder.
Top